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platin (c21,126), the same regimen was also the most expensive in the second line 
(c13,366), irinotecan/cetuximab in the third line (c25,633), and FOLFIRI/cetuximab 
in the fourth line (c6479). CONCLUSIONS: New chemotherapeutic agents are associ-
ated with improvements in survival time but also with substantial costs. Factors 
inﬂ uencing the selection of chemotherapy included: previous therapies, course of the 
disease, the patient’s performance status, adverse events after previous chemothera-
pies, and concomitant diseases. However, open-ended coverage policies for new che-
motherapeutic agents may prove difﬁ cult to sustain as costs continue to rise.
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OBJECTIVES: To describe chemotherapy regimens used in the ﬁ rst-, second-, third-, 
and fourth-line treatment of patients with metastatic colorectal cancer and to estimate 
costs of chemotherapy regimens, supportive care, and medical procedures in Slovenia 
(part of a multinational study in central Europe). METHODS: In this opinion-based 
study, necessary data were collected by online questionnaire. All information concern-
ing treatment of colorectal cancer was based on experts opinion from an oncology 
center in Slovenia. Oncologist had access to medical records of approximately 800 
patients treated in year 2008. RESULTS: The most commonly used regimen in the 
ﬁ rst line (30% of patients) was XELIRI (capecitabine, irinotecan) + bevacizumab. The 
most commonly prescribed regimen in the second (28%) and third lines (12%) was 
XELOX (capecitabine, oxaliplatin) + bevacizumab. XELIRI + bevacizumab was most 
commonly used in the fourth line (6%). Supportive care was not used in the ﬁ rst line 
with 9%, 55%, and 76% receiving it in the second, third, and fourth lines, respec-
tively. The most common treatment algorithm (21% of patients) was ﬁ rst-line XELIRI 
+ bevacizumab and second-line XELOX + bevacizumab. Mean regimen costs per 
patient were estimated from a public payer perspective. FOLFOX + cetuximab was 
the most expensive regimen in all lines. Costs of this regimen were c35,896 in the ﬁ rst 
line and c36,179 in the second, third, and fourth lines. CONCLUSIONS: More than 
50% of patients received an active treatment until the second line. Costs of treatment 
vary between lines. New chemotherapeutic agents are associated with improvements 
in survival time but also with substantial costs. Factors inﬂ uencing the selection of 
chemotherapy included: previous therapies, course of the disease, the patient’s perfor-
mance status, adverse events after previous chemotherapies, and concomitant diseases. 
However, open-ended coverage policies for new chemotherapeutic agents may prove 
difﬁ cult to sustain as costs continue to rise.
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OBJECTIVES: Colorectal cancer (CRC) is one of the most common forms of cancer 
in western countries and represents the second leading cause of cancer mortality in 
Europe (AIRTUM 2009). Early detection and removal of cancerous lesions can reduce 
CRC and mortality and improve patients’ quality of life (Taupin et al. 2006). The 
main literature on this topic refers to the United States and few studies have been 
conducted in Italy to date (Zappa et al. 1997; Tappenden 2007). Aim of the paper is 
to shed some light on the effectiveness and costs of screening programs in the Italian 
health-care system, presenting the results of a cost-effectiveness analysis of a CRC 
screening program in Italy. METHODS: We use as case study a Regional CRC screen-
ing program to determine the full costs and the effectiveness of the adopted techniques, 
FOBT combined with colonoscopy.The costs involved in each phase of the program 
are evaluated using a microcosting analysis. Effectiveness is valued in terms of early 
detected lesions and years of life gained. Cost and effectiveness data are used to 
estimate the costs for year of life gained, using a MISCAN-COLON Model© to simu-
late and compare two alternative scenarios, with or without the screening program. 
RESULTS: The preliminary results show that the screening will prevent almost 2.0 
deaths (11.2%) per 1000 screened individuals, corresponding to 19.4 years of life 
gained in 30 years with an incremental cost-effectiveness ratio of c2.400 for life-year 
gained. CONCLUSIONS: The results outpace those of previous studies (Sonnenberg 
2000), signaling an increasing effectiveness of CRC screening program. Besides, the 
paper highlights the importance of implementing a screening not only for the effects 
that prevention can have in clinical terms, but also for the economic impact of such 
a policy in relation to the long-term sustainability of health-care systems.
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OBJECTIVES: The objective of the study was to examine the direct medical cost of 
XELOX (capecitabine plus oxaliplatin) compared to FOLFOX (ﬂ uorouracil/leucovo-
rin plus oxaliplatin) for the treatment of advanced colon-rectum cancer in China. 
METHODS: Since the equal efﬁ cacy was already demonstrated by the published lit-
erature and local clinical guideline, cost minimization analysis was performed to 
compare the direct medical costs of XELOX and FOLFOX for the treatment of 
advanced colon-rectum cancer. The direct medical costs were associated with the drug 
costs, drug administration costs, hospitalization costs, and adverse events management 
costs. The costs were calculated based on a questionnaire survey from an expert panel 
of 23 pharmacists and 10 gastrointestinal surgeons and medical oncologists. 
RESULTS: According to the recommendation of expert panel, the standard treatment 
duration of XELOX and FOLFOX was eight cycles and 12 cycles, respectively. The 
drug cost of XELOX regimen was CNY 47,306 (US$6926), higher than FOLFOX by 
CNY 22,118 (US$3238). However, the cost increment of XELOX regimen was offset 
by the higher drug administration cost (deviation CNY 6,820), hospitalization cost 
(deviation CNY 10,200), and adverse events management cost (deviation CNY 7,710) 
of FOLFOX regimen. As a result, XELOX showed a signiﬁ cant overall cost savings 
of CNY 2612 (US$382) compared with FOLFOX. CONCLUSIONS: According to 
the study, XELOX is cost saving in comparison with FOLFOX for the treatment of 
advanced colon-rectum cancer in China, especially in the chemotherapy administra-
tion and hospitalization utilization.
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OBJECTIVES: To describe treatment patterns, resource use, and associated costs for 
cancer patients with malignant ascites (MA) receiving paracentesis in Germany. 
METHODS: The study was conducted as an observational, multicenter, prevalence-
based cohort study. Inclusion criteria were: age ≥18 years, diagnosis of ovarian or 
gastrointestinal carcinoma (CA) with MA, paracentesis as treatment option for MA 
at the time of enrolment. Resource consumption data were collected by chart review 
and patient questionnaire covering the time period from the ﬁ rst paracentesis docu-
mented in the study until ascites diagnosis retrospectively and subsequent paracenteses 
prospectively. Direct medical costs were analyzed from third-party payers’ (TPP) and 
patients’ perspective. RESULTS: A total of 29 patients (38% male) with a mean age 
of 65 ± 9 years were enrolled at 11 centers (six hospitals, ﬁ ve ofﬁ ce-based practices) 
between July 2008 and August 2009. Seven patients had ovarian CA (24%), 5 gastric 
CA (17%), and 17 other gastrointestinal CAs (59%). a total of 101 paracenteses were 
documented for all patients. From ascites diagnosis to death patients received on 
average 4.6 paracenteses. Mean time between two paracenteses was 11.9 ± 12.3 days. 
Data from 42 paracenteses were eligible for resource and cost analysis. Diuretics were 
applied in 57% of paracentesis units and human albumin in 29%. Intraperitoneal 
chemotherapy was applied rarely (5%). From TPPs’ perspective, mean total costs per 
paracentesis unit amounted to c1064 ± 1453, from patients’ perspective c17 ± 46. 
Direct medical costs per paracentesis unit varied from c671 ± 1070 at ofﬁ ce-based 
practices to c2.742 ± 1.535 at hospitals (inpatient treatment). CONCLUSIONS: This 
is the ﬁ rst comprehensive study evaluating the burden of MA in cancer patients 
undergoing paracentesis in Germany. Our ﬁ ndings indicate that the costs for paracen-
tesis range around c670 to c2700 depending on health-care setting. Our results might 
serve as a basis for further research on the economic implication of malignant ascites.
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OBJECTIVES: To assess the cost-effectiveness in Germany of primary prophylaxis 
(PP) with pegﬁ lgrastim versus 6- or 11-day ﬁ lgrastim (F6, F11) in the prevention of 
febrile neutropenia (FN) in non-Hodgkin lymphoma (NHL) patients receiving 
CHOP-14 chemotherapy and in breast cancer (BC) patients receiving TAC chemo-
therapy. METHODS: A payer perspective Markov model of febrile neutropenia pro-
phylaxis in chemotherapy patients was developed. PP was deﬁ ned as initiating 
prophylaxis with the ﬁ rst chemotherapy cycle. Model cycle length matches chemo-
therapy cycle length (CHOP-14:14 days, TAC: 21 days); model time horizon is the 
duration of chemotherapy (6 cycles). Cycle 1 FN risk with no prophylaxis was esti-
mated to be 21% for NHL CHOP-14 and 14% for BC TAC; all cycle relative risks 
of FN versus no prophylaxis for PP using Pegﬁ lgrastim, F6, and F11 were 0.25, 0.87 
and 0.61, respectively, based on published literature and meta-analyses. Pegﬁ lgrastim 
cost was estimated as c1686 per chemotherapy cycle; corresponding costs for F6 and 
F11 were c1347 and c2469 based on German national pricing. Incremental cost-
effectiveness ratios (ICERs) were calculated per FN events avoided. Costs and out-
comes were discounted (3%/year). Sensitivity analyses were performed. RESULTS: 
For NHL FN events per patient were 0.15, 0.76, and 0.47 for Pegﬁ lgrastim, F6, and 
F11, respectively. ICER for Pegﬁ lgrastim versus F6 was c1386 per FN avoided. For 
BC, corresponding FN events per patient were 0.09, 0.43, and 0.27. The ICER for 
Pegﬁ lgrastim versus F6 was c6651 per FN avoided. Pegﬁ lgrastim was dominant (less 
costly, more effective) compared with F11 in both populations. Results were most 
sensitive to baseline risk of FN, cost of prophylaxis and cost of FN events. CONCLU-
SIONS: Primary prophylaxis with pegﬁ lgrastim costs <c1400 per additional FN 
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avoided compared with 6-day ﬁ lgrastim for NHL patients treated with CHOP-14, and 
<c7000 for BC patients treated with TAC. Pegﬁ lgrastim dominated 11-day 
ﬁ lgrastim.
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OBJECTIVES: To asses the cost-effectiveness relationship of dasatinib in comparison 
to high dose of imatinib in the treatment of CML in patients with imatinib-resistant 
chronic myeloid leukemia in Spain. METHODS: A Markov model was developed to 
estimate, in the long term, the costs and clinical outcomes (life-years gained and 
quality-adjusted life-years gained) of dasatinib compared to imatinib in imatinib-
resistant patients. Four health states were considered in the analysis: Chronic phase; 
Accelerated phase; Blast phase; and Death. Cycle length is on a monthly basis and 
health effects and costs were counted until all patients reached the “death” health 
state. The efﬁ cacy outcomes are estimated from a direct comparison derived from the 
clinical trial BMS 017. The health-care resource use has been set up by a Spanish 
clinical expert and direct costs are in euros (2009). The perspective used is the Spanish 
Health System. Both costs and effects were discounted annually at 3.5%. The robust-
ness of the results was tested in deterministic sensitivity analyses. RESULTS: In the 
base-case scenario, treatment with dasatinib proves to be a dominant option with a 
lower total cost and a higher level of effectiveness (potential cost saving of c56,995 
and 0.19 QALY gained). The sensitivity analysis indicates that dasatinib remains as 
a dominant alternative in front of changes in the most relevant variables: costs, utility 
values, age at the start of the treatment, time horizon, and discount rate. CONCLU-
SIONS: Compared to imatinib, dasatinib shows a slower disease progression with 
relatively lower direct medical costs. Dasatinib can be regarded as a dominant treat-
ment option in patients with imatinib-resistant CML in the Spanish Health System.
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BACKGROUND: Chronic lymphocytic leukemia (CLL) is the most common of adult 
leukemias, comprising about 30–40% of all cases (Watson 2008). Incidence of CLL 
varies worldwide, being 4.3/100,000 in Caucasian men and increases with age, with 
median age at diagnosis of 64–70 years (Yamamoto 2005). In a phase III trial (CLL-8), 
the combined immunochemotherapy R-FC (rituximab plus ﬂ udarabine and cyclophos-
phamide) showed longer progression-free and overall survival, higher complete 
response rate, and longer duration of response than FC alone in previously untreated 
CLL patients. OBJECTIVES: To assess the incremental cost-utility ratio for R-FC 
versus FC alone in untreated CLL patients under the public payer perspective in Brazil. 
METHODS: The cost-effectiveness analysis was based on the pivotal study ML17102 
(CLL-8). a Markov model was developed consisting of three health states: “Progres-
sion-Free Survival” (PFS), “Progression,” and “Death”. The model cycle length is 
monthly and the time horizon of the analysis is 15 years. Costing was based on public 
sources. Only direct costs were considered in the calculation, including costs for treat-
ing severe adverse events and further treatment patterns. Costs were reported in 2010 
(US$1.00~$Brz1.8) Brazilian Reais and discounted at a 5% rate according to local 
guidelines for economic evaluation (Vianna 2007). RESULTS: R-FC combined 
therapy resulted in a gain of 1.031 life-years (Lys) (5.611 vs. 4.579) at an incremental 
cost of $Brz44,780. The ICER of R-FC versus FC is, therefore, estimated to be 
$Brz43,414 per LY gained. The probability of R-FC being cost-effective is 98.84%, 
considering a willingness-to-pay of R$100,000. CONCLUSIONS: In untreated CLL 
patients, R-FC therapy improves overall survival and progression-free survival com-
pared with FC alone. Results suggest that F-CR combined therapy is a cost-effective 
intervention for the Brazilian Public Healthcare System.
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OBJECTIVES: Zoledronic acid (ZOL) is the only bisphosphonate indicated for prevent-
ing skeletal-related events (SREs) in patients with bone metastases from prostate cancer 
(PC). We estimated and compared the cost-effectiveness of ZOL versus placebo for this 
indication in France, Germany, Portugal, and the The Netherlands. METHODS: Incre-
mental costs and quality-adjusted life-years (QALYs) associated with ZOL and placebo 
were estimated using a literature-based decision analytic model using data from a 
15-month randomized trial comparing ZOL (4 mg monthly; n = 214) with placebo (n 
= 208). The model included assumptions about SREs, mortality, drug and administration 
costs, SRE costs, quality of life, and therapy duration. SRE costs were estimated using 
Diagnosis Related Group tariff information (supplemented with published literature) in 
France and Germany, and published retrospective medical record review cost analyses 
in Portugal and the The Netherlands. RESULTS: Over 15 months, the cumulative 
projected SREs were 0.83 for ZOL and 1.66 for placebo. ZOL reduced SRE costs by 
c2659 to c4005, depending on the country. SRE cost savings were greatest in the The 
Netherlands, followed by Portugal, Germany, and France. ZOL reduced total costs 
(including drug costs) by c62 in Portugal and c301 in the The Netherlands, but increased 
costs by c562 in Germany and c1022 in France versus placebo. ZOL increased quality-
adjusted survival by 0.03566 QALY per patient, with an incremental cost per QALY 
gained versus placebo of c15,770 in Germany and c28,648 in France. In all countries, 
the cost-effectiveness ratio for ZOL was favorable and substantially below the interna-
tionally accepted c50,000/QALY threshold. Costs and QALYs were saved with ZOL 
in Portugal and the The Netherlands. CONCLUSIONS: In patients with bone metastasis 
from PC, ZOL is economically attractive. The cost-effectiveness ratio for ZOL is below 
standard cost-effectiveness thresholds used by most health-care systems. In Portugal and 
the The Netherlands, ZOL is cost-saving versus placebo.
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OBJECTIVES: The 74-month follow-up of the BIG 1–98 trial reported improved 
overall survival (OS) for 5 years letrozole (LET) versus tamoxifen (TAM; hazard ratio 
0.83; 95% CI 0.71, 0.97; P < 0.05). The 100-month follow-up of the ATAC trial did 
not show a signiﬁ cant difference in OS for anastrozole (ANA) versus TAM. Using 
reported differences in OS, we estimated the incremental cost per quality-adjusted 
life-year (QALY) gained for 5 years LET or ANA versus 5 years TAM in postmeno-
pausal women with endocrine-responsive breast cancer (ERBC), from a UK NHS 
perspective. METHODS: Annual survival probabilities postoperatively were extracted 
from BIG 1–98 and ATAC results. Survival was extrapolated to 20 years using data 
reported by the EBCTG for women receiving 5 years TAM. Conservatively, equivalent 
annual survival probabilities were assumed for TAM, LET, and ANA groups after 
follow-up. Published adverse event (AE) costs and 5-year costs for locoregional recur-
rence (LR) and metastases were applied. Published utility weights for disease-free 
survival with AEs, LR, and metastases were used. All costs and health beneﬁ ts were 
discounted at 3.5% annually. RESULTS: Over a 20-year period, the discounted 
additional treatment costs are £3618 for LET and £3736 for ANA. When accounting 
for AEs and reduced BC recurrence, the total cost difference between LET and TAM 
is £2964, and between ANA and TAM is £2929. The model estimated a difference in 
discounted QALYs of 0.297 for LET versus TAM, with an incremental cost per QALY 
gained of £9999. The incremental cost per QALY gained for ANA versus TAM is 
£46,829. CONCLUSIONS: Using updated OS data, economic analysis of 5 years LET 
or ANA versus 5 years TAM in postmenopausal women with ERBC suggests that LET 
is substantially more cost-effective than ANA. The current analysis is consistent with 
earlier extrapolations based on differences in time to recurrence.
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OBJECTIVES: The aim of a neurolytic sympathetic blockade is to reduce consumption 
or the side effects of opioids, to improve and enhance the analgesic response, and get 
efﬁ ciency of costs related to treatment. We assessed the cost-effectiveness (CEA) of 
superior hypogastric plexus inhibition (SHPI) in patients with cancer and visceral pain 
in the lower abdomen. METHODS: We conducted a CEA within a retrospective 
follow-up clinical study at the National Cancer Institute in Mexico City in patients 
>18 years with cancer and visceral pain. We assessed patients that underwent SHPI 
between March 2005 and June 2009. We evaluated the visual analog pain scale (VAS), 
drugs resource consumption, and medical direct costs. The measures were evaluated 
before and after (1 day, 1 week, 1, 2, 3, and 6 months) the procedure. Incremental 
cost-effectiveness ratio (ICER) was calculated. RESULTS: Twenty-six patients under-
went SHPI. They were matched with 26 patients with cancer and visceral pain 
managed with standard treatment (WHO analgesic ladder steps). The average cost per 
patient was not signiﬁ cantly different between treatment groups ($7372 vs. $6768 
MXP, P = 0.54); however, the effectiveness (treatment success: 50% decrease in drug 
consumption within 30 days) was much higher for SHPI (65% vs. 19%, P < 0.001). 
The ICER was $1308 (IC 95% 1104–1485) MXP per patient. CONCLUSIONS: SHPI 
was effective for treating visceral pain in cancer patients. The ICER ($1313 MXP) 
shows that SHPI is a cost-effectiveness alternative in Mexico (threshold of 1 GDP per 
capita).
